Need a new search?

If you didn't find what you were looking for, try a new search!

23 05, 2013

An Update from Seaside 5/22

By |2013-05-23T08:35:28-04:00May 23, 2013|Keeping You Informed, Seaside STX209|Comments Off on An Update from Seaside 5/22

Yesterday we received the following messages from Paul Wang, Vice President, Clinical & Medical Affairs at Seaside Therapeutics, Inc. Dear all - I wanted to let you know about a letter that we just posted [...]

20 12, 2012

Autism Speaks Lists Fragile X Syndrome Research on its Top Ten Autism Research Advances of 2012

By |2012-12-20T16:37:07-05:00Dec 20, 2012|Keeping You Informed, Research|Comments Off on Autism Speaks Lists Fragile X Syndrome Research on its Top Ten Autism Research Advances of 2012

Autism Speaks, the world's largest autism advocacy organization, recently released it's Top Ten Autism Research Advances of 2012. Included in this list is Fragile X research, mainly two drug studies of Arbaclofen. This is a [...]

6 11, 2012

Seaside Therapeutics Harbor-C Trials

By |2012-11-06T11:08:49-05:00Nov 6, 2012|Opportunities for Families|Comments Off on Seaside Therapeutics Harbor-C Trials

Seaside Therapeutics is studying the science of the brain and working to deliver treatments that improve the underlying causes of developmental disorders like Fragile X syndrome. Right now, Seaside is testing an investigational medicine called STX209 (arbaclofen) for individuals with Fragile X syndrome with social impairment. Thanks to the dedication and efforts of families, one of the clinical trials is almost complete.

21 09, 2012

Exciting Media Attention About Fragile X Clinical Trials

By |2012-09-21T10:40:33-04:00Sep 21, 2012|Keeping You Informed, News Reports and Commentaries|Comments Off on Exciting Media Attention About Fragile X Clinical Trials

The NFXF is pleased to see the media attention surrounding the latest news resulting from clinical trials for Fragile X syndrome treatments. Two members of the NFXF’s Scientific and Clinical Advisory Committee, Dr. Randi Hagerman, the NFXF’s co-founder, and Dr. Elizabeth Berry-Kravis, also a member of the NFXF’s Board of Directors, have been receiving prominent mention. The NFXF has been pleased to be able to assist its corporate partner, Seaside Therapeutics, with recruitment for this trial and others.

19 06, 2012

Breaking News – Seaside Therapeutics & Roche Announce Alliance to Advance Treatments

By |2012-06-19T05:36:28-04:00Jun 19, 2012|News Reports and Commentaries|Comments Off on Breaking News – Seaside Therapeutics & Roche Announce Alliance to Advance Treatments

Roche and Seaside Therapeutics announced today that they have entered into a collaboration to develop disease modifying treatments for Fragile X syndrome (FXS) and autism spectrum disorders (ASD), both neurodevelopmental disorders

Load More Posts